Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG)

Affiliations

¹ Canadian Agency for Drugs and Technologies in Health, Ottawa, Ontario, Canada.
² Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
³ Center for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.
⁴ Shire Pharmaceuticals, Lexington, Massachusetts, USA.
⁵ Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
⁶ CERobs Consulting, LLC, Chapel Hill, North Carolina, USA.
⁷ Pharmacy Practice & Administrative Sciences, University of Cincinnati College of Pharmacy, Cincinnati, Ohio, USA.
⁸ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
⁹ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹⁰ Center for Perinatal Research, Nationwide Children's Hospital and Department of Pediatrics, Ohio State University, Columbus, Ohio, USA.
¹¹ Health Outcomes, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
¹² Department of Pharmacoepidemiology, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.

PMID: 29733448
DOI: 10.1002/cpt.1086

Comment

Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG)

Hongbo Yuan et al. Clin Pharmacol Ther. 2018 Aug.

. 2018 Aug;104(2):239-241.

doi: 10.1002/cpt.1086. Epub 2018 May 7.

Authors

Affiliations

¹ Canadian Agency for Drugs and Technologies in Health, Ottawa, Ontario, Canada.
² Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
³ Center for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.
⁴ Shire Pharmaceuticals, Lexington, Massachusetts, USA.
⁵ Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
⁶ CERobs Consulting, LLC, Chapel Hill, North Carolina, USA.
⁷ Pharmacy Practice & Administrative Sciences, University of Cincinnati College of Pharmacy, Cincinnati, Ohio, USA.
⁸ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
⁹ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹⁰ Center for Perinatal Research, Nationwide Children's Hospital and Department of Pediatrics, Ohio State University, Columbus, Ohio, USA.
¹¹ Health Outcomes, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
¹² Department of Pharmacoepidemiology, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.

PMID: 29733448
DOI: 10.1002/cpt.1086

Abstract

On December 8, 2016, the New England Journal of Medicine published a sounding board on Real World Evidence (RWE)¹ by the US Food and Drug Administration (FDA) leadership. While the value of RWE based on nonrandomized observational studies was appreciated, such as for hypothesis generating, safety, and measuring quality in healthcare delivery, the authors expressed concerns on the quality of data sources and the ability of methodologies to control for confounding. In response, we offer a few considerations regarding these concerns.

PubMed Disclaimer

Comment on

Real-World Evidence - What Is It and What Can It Tell Us?
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM. Sherman RE, et al. N Engl J Med. 2016 Dec 8;375(23):2293-2297. doi: 10.1056/NEJMsb1609216. N Engl J Med. 2016. PMID: 27959688 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG)

Affiliations

Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG)

Authors

Affiliations

Abstract

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources